checkAd

     233  0 Kommentare Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips - Seite 2

    Van Houten’s appointment to Absci’s Board of Directors comes on the heels of Meta senior executive Dan Rabinovitsj and AI pioneer Joseph Sirosh’s appointment to the Absci Board of Directors last year. This reinforces the company’s commitment to assembling a distinguished group of industry leaders with a shared vision for advancing AI and science toward breakthrough therapeutics at the click of a button.

    About Absci
    Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing it to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s vision is to deliver breakthrough therapeutics at the click of a button, for everyone. Absci's headquarters is in Vancouver, WA, its AI Research Lab is in New York City, and its Innovation Center is in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), Twitter (@Abscibio), and YouTube.

    Lesen Sie auch

    Availability of Other Information about Absci
    Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

    Seite 2 von 4




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips - Seite 2 VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) - Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep …